Fang Z. Ni, Pharm.D.

is a Principal at Versant Ventures and acting CBO at Ridgeline.

Fang previously worked within Roche’s business development & licensing organization in the U.S. and Europe. He brings relevant skills and experience sourcing new opportunities and leading transactions across the fields of oncology, immunology, infectious and rare diseases. In his most recent role as Director, Global Oncology and Immuno-Oncology Business Development & Licensing, he was intimately involved in constructing an innovation strategy for cancer immunology and the molecular targeted therapy landscapes.

Getting in touch


Ridgeline Therapeutics GmbH
A Versant Ventures Discovery Engine

Aeschenvorstadt 36

CH 4051 Basel


Offices  and Labs

Ridgeline Therapeutics GmbH
Hochbergerstrasse 60C
CH 4057 Basel

A Versant Ventures Discovery Engine.




Imprint  /  Privacy Policy  /  Terms of Use

© 2018 Ridgeline Therapeutics GmbH